Science Explorer Back to mapMap

Most cited papers from Parkinson's Research and Education Foundation

Parkinson's Research and Education Foundation

What are the most cited papers from Parkinson's Research and Education Foundation?

The most cited paper from Parkinson's Research and Education Foundation is "Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial" (Jeffrey L. Cummings, Stuart Isaacson, Roger Mills et al., 2013), with 955 citations. Next come "The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension" (455) and "Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease" (303).

Showing 50 of 60 papers. Every paper with more than 18 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial Jeffrey L. Cummings, Stuart Isaacson, Roger Mills et al. · The Lancet 31 Oct 2013 955
2 The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension Christopher H. Gibbons, Peter N. Schmidt, Italo Biaggioni et al. · Journal of Neurology Open access 3 Jan 2017 455
3 Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease Joseph J. Jankovic, Ira J. Goodman, Beth Safirstein et al. · JAMA Neurology Open access 18 Jun 2018 303
4 Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease Michael A. Schwarzschild et al. · JAMA Neurology Open access Feb 2014 242
5 Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies Christopher H. Gibbons et al. · JAMA Open access 20 Mar 2024 199
6 Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3) Wolfgang Hermann Oertel, Karla Maria Eggert, Rajesh Pahwa et al. · Movement Disorders Open access 21 Aug 2017 168
7 Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study) Rajesh Pahwa, Caroline M. Tanner, Robert A. Hauser et al. · Movement Disorders Open access 4 Feb 2015 153
8 Droxidopa for the S hort‐ T erm T reatment of S ymptomatic N eurogenic O rthostatic H ypotension in P arkinson's D isease (n OH 306 B ) Robert A. Hauser, Stuart Isaacson, Jerome P. Lisk et al. · Movement Disorders Open access 9 Dec 2014 150
9 A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease François Tison, Charlotte Keywood, Mark Wakefield et al. · Movement Disorders 23 May 2016 141
10 Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study C. Warren Olanow, Stewart Alan Factor, Alberto J. Espay et al. · The Lancet Neurology 6 Dec 2019 132
11 Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial Peter A. LeWitt, Robert A. Hauser, Rajesh Pahwa et al. · The Lancet Neurology 18 Jan 2019 129
12 Haplotypes and gene expression implicate the MAPT region for Parkinson disease Jennifer E. Tobin et al. · Neurology Open access 28 May 2008 112
13 The Gly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study Jeanne C. Latourelle et al. · BMC Medicine Open access 5 Nov 2008 108
14 Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study Ana Westenberger et al. · Brain Open access159 authors 14 Jun 2024 102
15 Droxidopa in Patients with Neurogenic Orthostatic Hypotension Associated with Parkinson's Disease (NOH306A) Robert A. Hauser, L. Arthur Hewitt, Stuart Isaacson · Journal of Parkinson s Disease Open access 2014 98
16 Sublingual apomorphine (APL‐130277) for the acute conversion of OFF to ON in Parkinson's disease Robert A. Hauser, C. Warren Olanow, Bruce Dzyngel et al. · Movement Disorders Open access 19 Jul 2016 82
17 Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial Alberto J. Espay et al. · The Lancet Neurology 123 authors 15 Mar 2024 80
18 Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease Stuart Isaacson, Mark Lew, William G. Ondo et al. · Movement Disorders Clinical Practice Open access 25 May 2016 79
19 Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor Stuart Isaacson et al. · Tremor and Other Hyperkinetic Movements Open access 14 Aug 2020 77
20 Clinical implications of gastric complications on levodopa treatment in Parkinson's disease Ronald F. Pfeiffer, Stuart Isaacson, Rajesh Pahwa · Parkinsonism & Related Disorders Open access 11 May 2020 76
21 Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults Stuart Isaacson, William G. Ondo, Carlayne E. Jackson et al. · JAMA Neurology Open access 13 Jan 2020 70
22 Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension Robert A. Hauser, Stephane R. Heritier, Gerald J. Rowse et al. · Clinical Neuropharmacology Open access 23 Jun 2016 63
23 Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial Michel Peterschmitt et al. · Journal of Parkinson s Disease Open access 10 Dec 2021 62
24 Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease: recommendations from an expert panel Rajesh Pahwa, Stuart Isaacson, Diego R. Torres‐Russotto et al. · Expert Review of Neurotherapeutics 23 Jul 2018 62
25 Tardive Dyskinesia in Older Persons Taking Antipsychotics Leslie Citrome, Stuart Isaacson, Danielle Larson et al. · Neuropsychiatric Disease and Treatment Open access Oct 2021 57
26 Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study Stuart Isaacson, Babak Boroojerdi, Olga Waln et al. · Parkinsonism & Related Disorders 29 Jan 2019 57
27 Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations Richard Jackson, Matthew N. Brams, Leslie Citrome et al. · Neuropsychiatric Disease and Treatment Open access May 2021 56
28 Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis Clive G. Ballard, Stuart Isaacson, Roger Mills et al. · Journal of the American Medical Directors Association Aug 2015 56
29 Randomized, controlled trial of rasagiline as an add‐on to dopamine agonists in Parkinson's disease Robert A. Hauser, Dee E. Silver, Azhar Choudhry et al. · Movement Disorders 11 Jun 2014 56
30 ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study Robert A. Hauser, Rajesh Pahwa, Caroline M. Tanner et al. · Journal of Parkinson s Disease Open access 4 Aug 2017 52
31 Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials Jimin Ren, Richard B. Dewey, Austin Rynders et al. · Journal of Nanobiotechnology Open access 12 Dec 2023 51
32 Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease Michael Camilleri et al. · Annals of Internal Medicine Open access 7 Nov 2022 50
33 Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease Robert A. Hauser, Stuart Isaacson, Aaron L. Ellenbogen et al. · Parkinsonism & Related Disorders Open access 30 Mar 2019 50
34 IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease Robert A. Hauser, Alberto J. Espay, Aaron L. Ellenbogen et al. · JAMA Neurology Open access 14 Aug 2023 48
35 Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects Kelly E. Lyons, Joseph H. Friedman, Neal S. Hermanowicz et al. · Clinical Neuropharmacology 2010 48
36 Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis Angelo Antonini, Rajesh Pahwa, Per Odin et al. · CNS Drugs ReviewOpen access 21 Nov 2022 45
37 Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials Robert A. Hauser, Nobutaka Hattori, Hubert H. Fernandez et al. · Journal of Parkinson s Disease Open access 3 Sep 2021 45
38 Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts Tien Dam et al. · npj Parkinson s Disease Open access198 authors 27 Sep 2024 44
39 Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment Stuart Isaacson, Robert A. Hauser, Rajesh Pahwa et al. · Clinical Parkinsonism & Related Disorders Open access 2023 44
40 Targeting neurons in the gastrointestinal tract to treat Parkinson's disease Robert A. Hauser et al. · Clinical Parkinsonism & Related Disorders Open access 2019 44
41 Subcutaneous Levodopa Infusion for Parkinson's Disease: 1 ‐Year Data from the Open‐Label BeyoND Study Werner H Poewe et al. · Movement Disorders Open access 8 Sep 2021 42
42 Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303) Stuart Isaacson, Holly A. Shill, Steven A. Vernino et al. · Journal of Parkinson s Disease Open access 4 Aug 2016 42
43 Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis Clive G. Ballard, David L. Kreitzman, Stuart Isaacson et al. · Parkinsonism & Related Disorders 28 Jun 2020 40
44 Replication of association between ELAVL4 and Parkinson disease: the GenePD study Anita L. DeStefano et al. · Human Genetics Open access 28 Jun 2008 40
45 Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa Stuart Isaacson, Julia Skettini · Vascular Health and Risk Management Open access Apr 2014 39
46 Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective Stuart Isaacson, Stanley E. Fisher, Fiona Gupta et al. · Expert Review of Neurotherapeutics 4 Nov 2016 38
47 Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection Robert A. Hauser, Stuart Isaacson, Thomas Clinch · Parkinsonism & Related Disorders 27 Aug 2014 38
48 EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease Caroline M. Tanner, Rajesh Pahwa, Robert A. Hauser et al. · Journal of Parkinson s Disease Open access 17 Jan 2020 36
49 Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study Felix Agbo, Stuart Isaacson, Ramon A. Gil et al. · Neurology and Therapy Open access 15 May 2021 30
50 Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension Stuart Isaacson, Steven A. Vernino, Adam E. Ziemann et al. · Journal of the American Society of Hypertension Open access 4 Aug 2016 30

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.